Commission Implementing Regulation (EU) 2015/1982
of 4 November 2015
approving hexaflumuron as an existing active substance for use in biocidal products for product-type 18
(Text with EEA relevance)
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Whereas:
In accordance with Article 7(1)(b) of Delegated Regulation (EU) No 1062/2014, the opinion of the European Chemicals Agency was formulated on 3 December 2014 by the Biocidal Product Committee, having regard to the conclusions of the evaluating competent authority.
According to that opinion, biocidal products used for product-type 18 and containing hexaflumuron may be expected to satisfy the requirements laid down in Article 5 of Directive 98/8/EC provided that certain conditions concerning its use are complied with.
It is therefore appropriate to approve hexaflumuron for use in biocidal products for product-type 18 subject to compliance with certain specifications and conditions.
Since, pursuant to Article 90(2) of Regulation (EU) No 528/2012, substances for which the Member States' evaluation has been completed by 1 September 2013 should be approved in accordance with Directive 98/8/EC, the period of approval should be 5 years in accordance with the practice established under that Directive.
For the purposes of Article 23 of Regulation (EU) No 528/2012 however, hexaflumuron meets the conditions of Article 10(1)(a) and (d) of that Regulation and should therefore be considered a candidate for substitution.
Furthermore, pursuant to point 10 of Annex VI to Regulation (EU) No 528/2012, the competent authorities should also evaluate whether the conditions of Article 5(2) can be satisfied to decide if a biocidal product containing hexaflumuron can be authorised or not.
Since hexaflumuron meets the criteria for being very persistent (vP), very bioaccumulative (vB) and toxic (T) in accordance with the criteria laid down in Annex XIII to Regulation (EC) No 1907/2006, treated articles treated with or incorporating hexaflumuron should be appropriately labelled when placed on the market.
A reasonable period should be allowed to elapse before an active substance is approved, in order to permit interested parties to take the preparatory measures necessary to meet the new requirements.
The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Biocidal Products,
HAS ADOPTED THIS REGULATION: